Shares of MiNK Therapeutics, Inc. (INKT) surged on Tuesday morning after the company announced a new collaboration to develop a targeted cell therapy for pediatric cancers.
The stock is currently trading at $14.23, up $3.78 or 36.14%, on the Nasdaq. It opened at $15.71 after closing the previous session at $10.45. The stock has traded between $6.34 and $76.00 over the past 52 weeks.
MiNK Therapeutics said it has entered a strategic collaboration with C-Further, an international pediatric oncology therapeutics consortium, to develop a PRAME-targeted TCR-engineered invariant natural killer T (iNKT) cell therapy for pediatric cancers.
Under the agreement, the program could receive about $1.1 million in non-dilutive funding to support IND-enabling development, along with the potential for double-digit downstream commercial revenue participation.
The therapy will target PRAME, a tumor-associated antigen commonly expressed across several pediatric and adult cancers, including sarcomas, acute myeloid leukemia, and medulloblastoma. The program aims to advance a lead candidate toward first-in-human clinical studies in children.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.